Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | ATF1 | P18846 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16094689 | 1.00 | ESR1 (0.61) | ESR1SMN1; SMN2ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL9090117 | 0.86 | ESR1 (0.82) | ESR1CYP2D6CYP2C19HRH4ESR2 | |
| SCHEMBL11281707 | 0.85 | ESR1 (0.46) | ESR1SMN1; SMN2ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL23876121 | 0.81 | ESR1 (0.46) | ESR1SMN1; SMN2ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL29762427 | 0.80 | ESR1 (0.45) | ESR1SMN1; SMN2ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL23275205 | 0.80 | ESR1 (0.45) | ESR1SMN1; SMN2ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL23275208 | 0.80 | ESR1 (0.45) | ESR1SMN1; SMN2ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL28623660 | 0.77 | ESR1 (0.44) | ESR1SMN1; SMN2ALDH1A1KDM4EESR2 | |
| SCHEMBL28623661 | 0.77 | ESR1 (0.44) | ESR1SMN1; SMN2ALDH1A1KDM4EESR2 | |
| SCHEMBL6298554 | 0.76 | CYP2D6 (0.54) | ESR1KDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4048259-A1 | INHIBITORS OF RAF KINASES | Kinnate Biopharma Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-114845711-A | Inhibitors of RAF kinase | 金耐特生物制药公司 | 2022-08-02 | — | — | CN | disclosed |
| US-20210300904-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-09-30 | — | — | US | disclosed |
| CN-108467369-B | Biaryl amide compounds as kinase inhibitors | 诺华股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| WO-2021081375-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2019-04-02 | — | — | US | disclosed |
| EP-3299367-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| CN-105143209-B | Biaryl amide compounds as kinase inhibitors | 诺华股份有限公司 | 2018-03-13 | — | — | CN | disclosed |
| US-20170260207-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9694016-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| EP-2970216-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151616-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300904-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | ESR1 2072/4885SMN1; SMN2 3700/4885ALDH1A1 2750/4885 |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | ESR1 3372/4885SMN1; SMN2 3547/4885ALDH1A1 1592/4885 |
| US-20170260207-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | ESR1 3372/4885SMN1; SMN2 3547/4885ALDH1A1 1592/4885 |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | ESR1 3372/4885SMN1; SMN2 3547/4885ALDH1A1 1592/4885 |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | ESR1 3372/4885SMN1; SMN2 3547/4885ALDH1A1 1592/4885 |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | ESR1 3372/4885SMN1; SMN2 3547/4885ALDH1A1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.